Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Neostigmine for PDPH Prevention in C-Section
NCT04905953Phase 3Unknown
- Sponsor
- Cairo University
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of neostigmine in post-dural puncture headache (PDPH) (3 arms), sponsored by Cairo University. Primary endpoint: Incidence of Post-Dural Puncture Headache at 72 hours. Status: unknown.
02
Drugs
neostigmine
03
Conditions
post-dural puncture headache (PDPH)
Beyond the preview
Go deeper on NCT04905953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905953.